That work comes amid a recent resurgence in the study of psychedelic drugs like mushrooms and LSD for mental illness. While most of the research is being led by universities and non-profit research institutions, Compass, a for-profit company founded in 2016, sees itself as helping to fill in the gaps. [...]
Compass has also secured scientific oversight from respected researchers like Tom Insel, the former director of the National Institutes of Mental Health, and David Nutt, the former UK government drug czar, who serve on its board of advisors.
So far, Compass claims it has made two 250-gram batches of psilocybin, the equivalent of 20,000 doses of 25 mg of the drug. Although some of that will be tested for stability, the rest has been shaped into capsules. Those will soon be shipped to a handful of sites in Europe and North America, where Compass plans to use the psilocybin in clinical trials.
No comments:
Post a Comment